- Latest available (Revised)
- Original (As adopted by EU)
Commission Regulation (EC) No 1024/2009 of 29 October 2009 on the authorisation and refusal of authorisation of certain health claims made on food and referring to the reduction of disease risk and to children’s development and health (Text with EEA relevance)
When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.
Legislation.gov.uk publishes the UK version. EUR-Lex publishes the EU version. The EU Exit Web Archive holds a snapshot of EUR-Lex’s version from IP completion day (31 December 2020 11.00 p.m.).
This is the original version as it was originally adopted in the EU.
This legislation may since have been updated - see the latest available (revised) version
Application — Relevant provisions of Regulation (EC) No 1924/2006 | Applicant — Address | Nutrient, substance, food or food category | Claim | Conditions of use of the claim | Conditions and/or restrictions of use of the food and/or additional statement or warning | EFSA opinion reference |
---|---|---|---|---|---|---|
Article 14(1)(a) health claim referring to a reduction of a disease risk | Leaf Int and Leaf Holland, Hoevestein 26, 4903 SC Oosterhout NB, The Netherlands, and Leaf Suomi Oy, PO Box 25, FI-21381 Aura, Finland | Chewing gum sweetened with 100 % xylitol | Chewing gum sweetened with 100 % xylitol has been shown to reduce dental plaque. High content/level of dental plaque is a risk factor in the development of caries in children | Information to the consumer that the beneficial effect is obtained with a consumption of 2-3 g of chewing gum sweetened with 100 % xylitol at least 3 times per day after the meals | Q-2008-321 | |
Article 14(1)(b) health claim referring to children’s development and health | Danone SA, C/Buenos Aires, 21, 08029 Barcelona, Spain | Phosphorus | Phosphorus is needed for the normal growth and development of bone in children | The claim can be used only for food which is at least a source of phosphorus as referred to in the claim SOURCE OF [NAME OF VITAMIN/S] AND/OR [NAME OF MINERAL/S] as listed in the Annex to Regulation (EC) No 1924/2006 | Q-2008-217 |
Application — Relevant provisions of Regulation (EC) No 1924/2006 | Nutrient, substance, food or food category | Claim | EFSA opinion reference |
---|---|---|---|
Article 14(1)(b) health claim referring to children’s development and health | Lactoral | Lactoral helps to bring back the normal functioning of the alimentary tract during its microflora disturbances (for example in case of loose stools, after taking antibiotics, in case of intestinal disorders caused by enteric pathogens) | EFSA-Q-2008-269 |
Article 14(1)(b) health claim referring to children’s development and health | Lactoral | Lactoral is recommended in order to improve the general immunity by maintaining the microbiological balance | EFSA-Q-2008-477 |
Article 14(1)(b) health claim referring to children’s development and health | Lactoral | Lactoral helps to protect the alimentary system against enteric pathogens because of strong antagonistic properties and helps to build the natural intestinal barrier | EFSA-Q-2008-478 |
Article 14(1)(b) health claim referring to children’s development and health | Lactoral | Lactoral helps to maintain natural intestinal microflora during travel, changing the climatic zone or a diet, especially in poor hygiene conditions | EFSA-Q-2008-479 |
Article 14(1)(b) health claim referring to children’s development and health | Lactoral | Lactoral contains living probiotic bacteria with strong ability to intestinal tract colonisation, isolated from healthy, naturally fed infant | EFSA-Q-2008-480 |
Article 14(1)(b) health claim referring to children’s development and health | Mumomega® | Mumomega® provides the nourishments that support healthy central nervous system development | EFSA-Q-2008-328 |
Article 14(1)(b) health claim referring to children’s development and health | Efalex® | Efalex® may help maintain coordination | EFSA-Q-2008-121 |
Article 14(1)(b) health claim referring to children’s development and health | Efalex® | Efalex® may help maintain concentration | EFSA-Q-2008-317 |
Article 14(1)(b) health claim referring to children’s development and health | Efalex® | Efalex® may help maintain and support brain development and function | EFSA-Q-2008-318 |
Article 14(1)(b) health claim referring to children’s development and health | Efalex® | Efalex® may help maintain learning ability | EFSA-Q-2008-319 |
Article 14(1)(b) health claim referring to children’s development and health | Efalex® | Efalex® may help maintain and support eye development and function | EFSA-Q-2008-320 |
Article 14(1)(b) health claim referring to children’s development and health | Eye q baby® | Eye q baby® provides the nourishments that support healthy central nervous system development | EFSA-Q-2008-119 |
Article 14(1)(b) health claim referring to children’s development and health | Eye q® | Eye q® provides the nourishments that help children to maintain healthy brain functions | EFSA-Q-2008-329 |
Article 14(1)(b) health claim referring to children’s development and health | Eye q® | Eye q® provides the nourishments that help children to maintain concentration levels | EFSA-Q-2008-330 |
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: